CL2011002460A1 - Torta liofilizada que comprende un inhibidor de proteasoma derivado del acido protonico, una ciclodextrina, y al menos un agente espesante y/o un surfactante; metodo para su fabricacion; y su uso en el tratamiento de mieloma multiple. - Google Patents

Torta liofilizada que comprende un inhibidor de proteasoma derivado del acido protonico, una ciclodextrina, y al menos un agente espesante y/o un surfactante; metodo para su fabricacion; y su uso en el tratamiento de mieloma multiple.

Info

Publication number
CL2011002460A1
CL2011002460A1 CL2011002460A CL2011002460A CL2011002460A1 CL 2011002460 A1 CL2011002460 A1 CL 2011002460A1 CL 2011002460 A CL2011002460 A CL 2011002460A CL 2011002460 A CL2011002460 A CL 2011002460A CL 2011002460 A1 CL2011002460 A1 CL 2011002460A1
Authority
CL
Chile
Prior art keywords
cyclodextrin
treatment
multiple myeloma
freeze
surfactant
Prior art date
Application number
CL2011002460A
Other languages
English (en)
Inventor
Bricout Denis
Cambourieux Helena
Original Assignee
Teva Sante
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Sante filed Critical Teva Sante
Publication of CL2011002460A1 publication Critical patent/CL2011002460A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Una torta liofilizada que comprende A) Una droga, siendo la droga un compuesto inhibidor de proteasoma, B) Una ciclodextrina y C) Al menos un miembro seleccionado del grupo consistente en agentes espesantes y surfactantes; método de preparación; y su uso para el tratamiento del mieloma múltiple.
CL2011002460A 2009-04-03 2011-10-03 Torta liofilizada que comprende un inhibidor de proteasoma derivado del acido protonico, una ciclodextrina, y al menos un agente espesante y/o un surfactante; metodo para su fabricacion; y su uso en el tratamiento de mieloma multiple. CL2011002460A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16652909P 2009-04-03 2009-04-03
EP09305291A EP2238973A1 (en) 2009-04-07 2009-04-07 Lyophilized preparations of proteasome inhibitors
US28895509P 2009-12-22 2009-12-22
PCT/US2010/029597 WO2010114982A2 (en) 2009-04-03 2010-04-01 Lyophilization cakes of proteasome inhibitors

Publications (1)

Publication Number Publication Date
CL2011002460A1 true CL2011002460A1 (es) 2012-09-14

Family

ID=41130433

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2011002460A CL2011002460A1 (es) 2009-04-03 2011-10-03 Torta liofilizada que comprende un inhibidor de proteasoma derivado del acido protonico, una ciclodextrina, y al menos un agente espesante y/o un surfactante; metodo para su fabricacion; y su uso en el tratamiento de mieloma multiple.

Country Status (16)

Country Link
US (1) US8785418B2 (es)
EP (2) EP2238973A1 (es)
JP (1) JP5722871B2 (es)
KR (1) KR20120016082A (es)
CN (1) CN102387790B (es)
AR (1) AR084663A1 (es)
AU (1) AU2010232632C1 (es)
BR (1) BRPI1006633A2 (es)
CA (1) CA2757463A1 (es)
CL (1) CL2011002460A1 (es)
IL (1) IL215325A (es)
MX (1) MX2011010422A (es)
NZ (1) NZ596056A (es)
TW (1) TWI484981B (es)
WO (1) WO2010114982A2 (es)
ZA (1) ZA201107852B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5783659B2 (ja) * 2009-12-22 2015-09-24 セファロン、インク． プロテアソーム阻害剤およびその調製、精製および使用のための方法
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
KR101530942B1 (ko) 2010-03-18 2015-06-23 이노파르마, 인코포레이티드 안정한 보르테조밉 포뮬레이션
US8962572B2 (en) 2010-10-05 2015-02-24 Fresenius Kabi Usa, Llc Bortezomib formulations
TW201309303A (zh) * 2011-03-03 2013-03-01 Cephalon Inc 用於治療狼瘡的蛋白酶體抑制劑
CN102784114B (zh) * 2011-05-14 2016-03-02 山东新时代药业有限公司 一种硼替佐米冻干粉针及其制备方法
CA2833775A1 (en) * 2011-06-22 2012-12-27 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
CA2784240C (en) * 2012-03-27 2014-07-08 Innopharma, Inc. Stable bortezomib formulations
EA021179B1 (ru) * 2012-06-15 2015-04-30 Ощество С Ограниченной Ответственностью "Тева" Лиофилизат соединения бороновой кислоты
WO2014072985A1 (en) * 2012-11-06 2014-05-15 Natco Pharma Limited Novel boronic acid derivatives as anti cancer agents
CN103897027A (zh) * 2012-12-29 2014-07-02 曹亚英 关键中间体晶型，制备方法及其在硼替佐米合成中的运用
CN103897026A (zh) * 2012-12-29 2014-07-02 朱继东 硼替佐米关键中间体的晶型，制备方法及其运用
WO2014102755A1 (en) * 2012-12-31 2014-07-03 Shilpa Medicare Limited Bortezomib formulations
CN103070835B (zh) * 2013-01-31 2015-01-07 江苏奥赛康药业股份有限公司 一种含硼替佐米的冻干组合物及其制备方法
WO2014161072A1 (en) * 2013-04-02 2014-10-09 The Governing Council Of The University Of Toronto Α-boryl isocyanides, boropeptides and boron heterocycles
CN103212055B (zh) * 2013-04-19 2014-11-05 海南锦瑞制药股份有限公司 一种硼替佐米的药物组合物及其制备方法
WO2014190992A1 (en) * 2013-05-29 2014-12-04 Gea Process Engineering A/S Method of providing inline sterile freeze drying of a product in trays accommodated in a trolley, system for carrying out the method, and use of the method
CN103720666B (zh) * 2013-12-16 2015-11-25 亿腾药业（泰州）有限公司 一种注射用硼替佐米冻干制剂的制备方法
US10144761B2 (en) 2015-06-19 2018-12-04 Hanlin Scientific Inc. Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
EP3310360B1 (en) * 2015-06-19 2024-03-27 Beijing Artivila BioPharma Co. Ltd. Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
WO2018038687A1 (en) 2016-08-22 2018-03-01 Mustafa Nevzat Ilaç Sanayii A.Ş. Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex
CN106176637A (zh) * 2016-08-24 2016-12-07 江苏豪森药业集团有限公司 硼替佐米的冻干制剂及其制备方法
MX2019007433A (es) * 2016-12-22 2019-08-16 Genentech Inc Metodos y formulaciones para reducir el tiempo de reconstitucion de los polipeptidos liofilizados.
RU2659160C1 (ru) * 2017-07-10 2018-06-28 Акционерное Общество "Фарм-Синтез" Способ получения лиофилизата бортезомиба и фармацевтическая композиция, содержащая бортезомиб в форме стабильного лиофилизованного продукта, полученная указанным способом
CN110540547A (zh) * 2018-05-28 2019-12-06 秦艳茹 一种肽硼酸酯类化合物的合成与用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5835968B2 (ja) 1974-02-25 1983-08-05 帝人株式会社 サイクロデキストリン包接化合物の製造法
GB1584462A (en) 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
JPS5920230A (ja) 1982-07-19 1984-02-01 チバ−ガイギ−・アクチエンゲゼルシヤフト ピルプロフエン含有薬剤
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
FR2593809B1 (fr) 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
JPS62281855A (ja) 1986-05-29 1987-12-07 Daikin Ind Ltd ビタミン，ビタミン誘導体，またはホルモンを含有する包接化合物
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
GB8813682D0 (en) 1988-06-09 1988-07-13 Reckitt & Colmann Prod Ltd Pharmaceutical compositions
JPH035438A (ja) 1989-05-31 1991-01-11 Kaken Pharmaceut Co Ltd フルルビプロフェン包接化合物およびこの包接化合物を用いる消炎鎮痛剤
CA2013485C (en) 1990-03-06 1997-04-22 John Michael Gardlik Solid consumer product compositions containing small particle cyclodextrin complexes
FR2663225B1 (fr) 1990-06-14 1994-11-04 Lafon Labor Nouvelle utilisation du modafinil.
US5024997A (en) 1990-06-22 1991-06-18 American Home Products Corporation Palatable ibuprofen solutions
JP3176716B2 (ja) * 1991-06-21 2001-06-18 武田薬品工業株式会社 溶解性が向上した難水溶性薬物組成物
FR2684875B1 (fr) 1991-12-13 1995-05-24 Lafon Labor Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique.
US5843347A (en) 1993-03-23 1998-12-01 Laboratoire L. Lafon Extrusion and freeze-drying method for preparing particles containing an active ingredient
FR2702968B1 (fr) 1993-03-23 1995-06-23 Lafon Labor Procédé de préparation de particules renfermant un ingrédient actif par extrusion et lyophilisation .
US5866162A (en) 1993-08-10 1999-02-02 Smithkline Beecham P.L.C. Pharmaceutical composition containing a drug/β-cyclodextrin complex in combination with an acid-base couple
US5618845A (en) 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
US5874418A (en) 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6077871A (en) 1997-11-26 2000-06-20 Pfizer Inc. Droloxifene pharmaceutical compositions
US6200968B1 (en) 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6346548B1 (en) 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
US6455588B1 (en) 1999-08-20 2002-09-24 Cephalon, Inc. Compositions including modafinil for treatment of eating disorders and for appetite stimulation
EP3078667B1 (en) * 2001-01-25 2018-11-21 The United States of America, represented by the Secretary, Department of Health and Human Services Formulation of boronic acid compounds
US7576206B2 (en) * 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
ME01975B (me) 2004-03-30 2015-05-20 Millennium Pharm Inc Sinteza jedinjenja estra organoborne kiseline i organoborne kiseline
WO2006063154A1 (en) * 2004-12-07 2006-06-15 Proteolix, Inc. Composition for proteasome inhibition
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US20070093449A1 (en) * 2005-10-14 2007-04-26 De Porre Peter M R Novel IV formulation of tipifarnib
PL2094308T3 (pl) * 2006-11-21 2011-06-30 Novartis Ag Trwały preparat pozajelitowy zawierający inhibitor RSV o strukturze benzodiazepiny
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors

Also Published As

Publication number Publication date
TWI484981B (zh) 2015-05-21
JP2012522795A (ja) 2012-09-27
CN102387790B (zh) 2014-12-10
AR084663A1 (es) 2013-06-05
TW201039865A (en) 2010-11-16
AU2010232632A1 (en) 2011-11-24
JP5722871B2 (ja) 2015-05-27
NZ596056A (en) 2012-10-26
BRPI1006633A2 (pt) 2019-09-24
AU2010232632C1 (en) 2016-09-22
ZA201107852B (en) 2012-07-25
EP2238973A1 (en) 2010-10-13
IL215325A0 (en) 2011-12-29
US8785418B2 (en) 2014-07-22
EP2413916A2 (en) 2012-02-08
CN102387790A (zh) 2012-03-21
WO2010114982A3 (en) 2011-09-01
AU2010232632B2 (en) 2016-04-21
MX2011010422A (es) 2011-10-17
IL215325A (en) 2016-06-30
WO2010114982A2 (en) 2010-10-07
US20120035133A1 (en) 2012-02-09
KR20120016082A (ko) 2012-02-22
CA2757463A1 (en) 2010-10-07

Similar Documents

Publication Publication Date Title
CL2011002460A1 (es) Torta liofilizada que comprende un inhibidor de proteasoma derivado del acido protonico, una ciclodextrina, y al menos un agente espesante y/o un surfactante; metodo para su fabricacion; y su uso en el tratamiento de mieloma multiple.
CL2014003171A1 (es) Composicion liofilizada que comprende al menos una benzodiazepina de formula (i), al menos un excipiente higroscopico seleccionado de disacaridos y dextrano; metodo de preparacion de la composicion farmaceutica.
CO6720961A2 (es) Imidazopiridazinas sustituidas
CL2011002878A1 (es) Compuestos derivados de tieno[2,3-b]piridinas, inhibidores de la replicacion del virus vih; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para prevenir o tratar una infeccion por vih.
CL2008003405A1 (es) Compuestos derivados de tienopiridina, inhibidores de la enzima integrasa del vih; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una infeccion por vih.
CL2014003121A1 (es) Formulacion liquida que comprende propilenglicol y un inodilatador, un inhibidor de la enzima convertidora de angiotensina o una combinacion de ambos; proceso para prepararla; kit; y metodo de tratamiento de una enfermedad cardiaca y/o hipertension.
ECSP14024082A (es) Material no viable derivado de probióticos para la prevención y tratamiento de infecciones
CL2011002082A1 (es) Composicion farmaceutica que comprende un inhibidor de nucleosido polimerasa y un inhibidor de proteasa macrociclica; proceso para preparar dicha composicion farmaceutica; metodo para tratar o mejorar una infeccion con virus de la hepatitis c, fibrosis hepatica y alteracion de la funcion hepatica.
UY32456A (es) Composicion famaceutica, forma farmaceutica, procedimiento para su preparación, metodos de tratamiento
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
PE20140255A1 (es) Tableta dispersable en forma oral
DOP2016000253A (es) Nuevos compuestos
CL2014000470A1 (es) Compuestos derivados del acido 2-oxo-piridin-3-carboxilico; composicion farmaceutica; combinacion; y su uso para tratar o mejorar una infeccion bacteriana.
CL2013001935A1 (es) Formulacion ácida acuosa que comprende un primer péptido enlazado a fluorocarburo; metodo para obtener dicha formulación; uso de dicha formulación para tratar o prevenir infeccion patógena, una enfermedad autoinmunitaria o cancer.
AR082423A1 (es) Composicion detergente liquida
MX336276B (es) Composiciones de agentes tensoactivos y uso para composiciones acuosas.
CL2011001405A1 (es) Procedimiento para la preparacion de n-[2-(7-metoxi-1-naftil)etil]acetamida, agometalina.
CR20160235A (es) Tienopirimidinas como inhibidores mknk1 y mknk2
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
CO6551731A2 (es) Composiciòn de combinaciòn que comprende como ingrediente activo l- carnitina o propionil l- carnitina, para la prevenciòn o tratamiento de insuficienca venosa crònica
BR112013020841B8 (pt) Processo para preparar produtos que compreendem ativos estabilizados e composições que compreendem os mesmos
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
BR112013019924A8 (pt) Composições para cuidado oral
CL2017001818A1 (es) Bacteria de ácido láctico y su uso para el tratamiento de mastitis
EP2314275A3 (en) Compositions comprising a low-dp polymerized surfactant and a micellar thickener